| Comparators (medicinal and non medicinal) for marketing authorization, for public health, for payers and at the European level. | |
| | |
MedLine Citation:
|
PMID: 20854755 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Drug evaluation is based on comparison. Thus, the choice of the comparator for any new treatment becomes a key issue, especially when there are great differences in medical practice and of use conditions of the comparators depending on the geographical zones and their evolution with time. The choice of the comparators must satisfy sometimes different expectations from the registration authorities and for insurance coverage. The universal comparator that allows answering all the clinical assessment questions does not exist. Placebo, when it can be used, remains a reference for the MA (marketing authorisation) application, but does not exclude the use of the reference drug available on the market and prescribed under optimal efficacy conditions. The reference treatment is sometimes a difficult choice due to the absence of validated therapeutic recommendations or if the recommendations vary depending on the countries. The expansion and international harmonization of prescription guidelines (clinical practice guidelines) would reinforce the robustness and efficiency of clinical research efforts with respect to the relevance of the comparison to reference treatments. This principle also applies to the use of a non-drug comparator when it has been recognized as the reference comparator in the treatment of the pathology in question. In as much as possible, the search for a consensus must also aim at defining in the clinical development recommendations significant thresholds for the size of evaluated effects. Optimization of the information made available after clinical trials could also be helped by the development of use of methodologies that allow assessing superiority on secondary criteria during a non-inferiority study on the main criterion. Finally, the development of early scientific consultations by the Haute Autorité de Santé (HAS, French Health Authority) would contribute to adapt phase III clinical trials better to questions concerning the assessment of the clinical added value of the medicinal products evaluated. |
| | |
Authors:
|
Driss Berdaï; Jean-Michel Hotton; Philippe Lechat; |
Related Documents
:
|
1260615 - Management of "psychosomatic" problems in clinical practice. 9691785 - Steps towards a theory of medical practice. 20350905 - American association of clinical endocrinologists protocol for standardized production ... 22330265 - Determinants of sustainability in solid waste management - the gianyar waste recovery p... 6367535 - Anaesthetic management during repair of tracheo-oesophageal fistula. 21885485 - Early management of newly diagnosed rheumatoid arthritis by canadian rheumatologists: a... |
Publication Detail:
|
Type: Journal Article Date: 2010-09-21 |
Journal Detail:
|
Title: Thérapie Volume: 65 ISSN: 0040-5957 ISO Abbreviation: Therapie Publication Date: 2010 Jul-Aug |
Date Detail:
|
Created Date: 2010-09-21 Completed Date: 2010-12-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0420544 Medline TA: Therapie Country: France |
Other Details:
|
Languages: eng Pagination: 329-34 Citation Subset: IM |
Copyright Information:
|
© 2010 Société Française de Pharmacologie et de Thérapeutique. |
Affiliation:
|
CHU de Bordeaux, Bordeaux, France. driss.berdai@u-bordeaux2.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic
/
standards* Drug Approval / legislation & jurisprudence* Drug Evaluation Europe European Union Guidelines as Topic Humans Marketing Public Health / standards* |
| Investigator | |
Investigator/Affiliation:
|
Alexandre Barna / ; Laurent Becquemont / ; Jean-François Bergman / ; Corine Bernaud / ; Isabelle Boucot / ; Isabelle Cheiney / ; Michel Cucherat / ; Anne d'Andon / ; Jérôme d'Enfert / ; Alain Francillon / ; Elisabeth Frauger / ; Danièle Girault / ; Jean-Marc Harlin / ; Alain Joseph / ; Catherine Lassale / ; Florence Mahlberg-Gaudin / ; Thierry Moreau-Defarges / ; Mira Pavlovic / ; Sophie Ravoire / ; Lise Rochaix / ; Eric Vicaut / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical trials and E-health: impact of new information technology applied to clinical trials (inclu...
Next Document: How to best define target populations of medicines in view of their coverage by the national health ...